X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Knoll Pharma: An update - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Aug 29, 2001

    Knoll Pharma: An update

    Knoll Pharma is a leading player in the domestic insulin, anti-diabetic, pain control and antacid market with around 55% market share in the insulin business. However, most of the company's drugs are under DPCO coverage. The company’s financials went through a bumpy ride in the last six months due to two important price changes ordered by DPCO.

    Knoll Pharma- A bumpy ride
    Particulars 1QFY01 1QFY02 % Change 2QFY01 2QFY02 % Change
    Sales (Rs. Mn.) 731 813 11.2% 897 932 3.9%
    Operating Profit Margins (%) 16.8 13.8 _ 14.9 17.6 _
    Profit Before Tax (Rs.Mn.) 147 125 -15.0% 143 248 73.4%
    PBT (%) 20.1 15.4 _ 15.9 26.6 _

    In the first quarter, NPPA reduced prices of Ibuprofen (pain management bulk drug), which adversely impacted the company. As Knoll pharma is a market leader in the Ibuprofen market, the price cut had a severe impact on the company’s financials. The impact was evident from a 300 basis points fall in operating margins. PBT dropped 15%.

    However, there was some good news on the cards also. The NPPA revised the prices of Insulin injections in March. Since then, Insulin vial prices increased in the range of 22%-25%, directly adding to the company’s bottomline. The effect of price hike was quite evident in 2QFY02. While sales grew by just 4%, PBT jumped 73%. Operating margins went up by 270 basis points. Insulin remains the biggest revenue generator for the company, contributing around 40% of the company’s revenues

    Following the parent company’s consolidation with Abbott Inc., the latter recently announced an open offer to acquire 20% of the company’s equity. A major concern for Knoll Pharma ,till recently, was the absence of a strong parent pipeline unlike other pharma MNC companies. The product basket of the company is expected to receive a boost with a new parent in place. However, there is still uncertainty on this matter as Abbott Inc, also has a 51% subsidiary operating in India.

    Another obvious concern for the stock is its high DPCO exposure, the profitability of the company remains dependent on the vagaries of NPPA. The DPCO exposure of the company is close to 60%.

    Particulars Hoechst SmithKline
    Pharma
    Glaxo Pfizer Knoll
    CMP (Rs.) 401 135 268 429 260
    Market Capitalisation (Rs. Mn.) 9236 3960 16005 10054 4212
    Sales- FY02 E 5365 3568 7665 3710 3320
    Market Cap/sales (x) 1.7 1.1 2.1 2.7 1.3
    P/e (x) 12.3 11.4 27.8 13.1 8

    At the current market price of Rs 260, the stock is trading at a P/E of 8x FY02 expected earnings. The stock trades at considerable discount to its peers. Knoll Pharma’s financials are expected to look up in the short term, mirroring the Insulin price revision. However, in the long term competition is expected to set in this business with other domestic players evincing interest in entering the Insulin market. Further, the company desperately needs to introduce new products to fuel growth.

     

     

    Equitymaster requests your view! Post a comment on "Knoll Pharma: An update". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    ABBOTT INDIA SHARE PRICE


    Aug 22, 2017 (Close)

    TRACK ABBOTT INDIA

    • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    ABBOTT INDIA 8-QTR ANALYSIS

    Detailed Quarterly Results With Charts

    COMPARE ABBOTT INDIA WITH

    MARKET STATS